WA
Consensus Narrative from 7 Analysts
NOPAIN Policy May Increase EXPAREL Access, Yet Patent Risks Could Impact Future
Key Takeaways Implementation of NOPAIN policy and new J-code could boost EXPAREL access and revenue growth. Strategic partnerships and product development, including ZILRETTA and iovera°, enhance market opportunities and future earnings potential.
View narrativeUS$24.71
FV
9.8% overvalued intrinsic discount6.51%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
14 days ago author updated this narrative